US EditionAdvanCell Receives $18M in Federal Funding
3 Articles
3 Articles
AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for 'Defeating Prostate Cancer with Targeted Alpha Therapy'
SYDNEY -- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’.
AdvanCell Receives $18M in Federal Funding
AdvanCell, a Sydney, Australia-based clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, received $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’. ìWith the support from the Medical Research Future Fund (MRFF) Frontiers Initiative, the goal of the multidisciplinary multi-institutional inves…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
